Seminars in Hematology
Volume 40, Issue 2 , Pages 116-123 , April 2003

Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases

References 

  1. Andersson J. Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand J Infect Dis. 1996;100(suppl):72–82
  2. Baranski B, Armstrong G, Truman JT, et al.  Epstein-Barr virus in the bone marrow of patients with aplastic anemia. Ann Intern Med. 1988;109:695–704
  3. Bottino C, Falco M, Parolini S, et al.  NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med. 2001;194:235–246
  4. Callan MFC, Steven N, Krausa P, et al.  Large clonal expansion of CD8+ T cells in acute infectious mononucleosis. Nat Med. 1996;2:906–911
  5. Callan MFC, Tan L, Anels N, et al.  Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med. 1998;187:1395–1402
  6. Coffey AJ, Brooksbank RA, Brandau O, et al.  Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129–135
  7. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481–492
  8. Cohen JI. Epstein-Barr virus infections, including infectious mononucleosis. In: ed 15.  Braunwald E,  Fauci AS,  Kasper DL, et al. editor. Harrison's Principles of Internal Medicine. New York, NY: McGraw Hill; 2001;p. 1109–1111
  9. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine. 1991;70:137–160
  10. Comoli P, Labirio M, Basso S, et al.  Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active viral replication. Blood. 2002;99:2592–2598
  11. Crotty S, Kersh EN, Cannons J. SAP is required for generating long-term humoral immunity. Nature. 2003;421:282–287
  12. Czar MJ, Kersh EN, Mijares LA, et al.  Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci USA. 2001;98:7449–7454
  13. Davis CL, Wood BL, Sabath DE, et al.  Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 1998;66:1770–1779
  14. Emanuel DJ, Lucas KG, Mallory GB, et al.  Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation. 1997;63:1691–1694
  15. Enberg RN, Eberle BJ, Williams RC. T and B cells in the peripheral blood during infectious mononucelosis. J Infect Dis. 1974;130:104–111
  16. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964;1:702–703
  17. Faye A, Quartier P, Reguerre Y, et al.  Chimaeric anti-CD20 monoclonal antibody (rituximab) in posttransplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001;115:112–118
  18. Finch SC. Laboratiory findings in infectious mononucleosis. In:  Carter RL,  Penman HG editor. Infectious Mononucleosis. Oxford, UK: Blackwell Scientific; 1969;p. 47–62
  19. Glaser SL, Lin RJ, Stewart SL, et al.  Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data. Int J Cancer. 1997;70:375–382
  20. Gottschalk S, Heslop HE, Rooney CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res. 2002;84:175–201
  21. Green M, Kaufmann M, Wilson J, et al.  Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation. Clin Infect Dis. 1997;25:1344–1349
  22. Haque T, Taylor C, Wilkie GM, et al.  Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein-Barr virus-specific cyototoxic T cells. Transplantation. 2001;72:1399–1402
  23. Haynes BF, Schooley RT, Payling-Wright CR, et al.  Emergence of supressor cells of immunoglobulin synthesis during acute Epstein-Barr virus-induced infectious mononucleosis. J Immunol. 1979;123:2095–2101
  24. Hislop AD, Annels NE, Gudgeon NH, et al.  Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med. 2002;195:893–905
  25. Horowitz CA, Moulds J, Henle W, et al.  Cold agglutinins in infectious mononucleosis and heterophile-antibody-negative mononucleosis-like syndromes. Blood. 1977;50:195–202
  26. Imashuku S, Hibi S, Ohara T, et al.  Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunotherapy. Blood. 1999;93:1869–1874
  27. Khanna R, Bell S, Sherritt M, et al.  Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA. 1999;96:10391–10396
  28. Khanna R, Tellam J, Duraiswamy J, et al.  Immunotherapeutic strategies for EBV-associated malignancies. Trends Mol Med. 2001;7:270–276
  29. Kikuta H, Sakiyama Y, Matsumoto S, et al.  Fatal Epstein-Barr virus-associated hemophagocytic syndrome. Blood. 1993;82:3259–3264
  30. Kovalchuk AL, Qi C-F, Torrey TA, et al.  Burkitt lymphoma in the mouse. J Exp Med. 2000;192:1183–1190
  31. Latour S, Gish G, Helgason CD, et al.  Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol. 2001;2:681–690
  32. Lazarus KH, Baehner RL. Aplastic anemia complication infectious mononucleosis: A case report and review of the literature. Pediatrics. 1981;67:907–910
  33. Levy M, Kelly JP, Kaufman DW, et al.  Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: A report from the International Agranulocytosis and Aplastic Anemia Study. Ann Hematol. 1993;67:187–190
  34. Malouf MA, Chhajed PN, Hopkins P, et al.  Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant. 2002;21:547–554
  35. McDiarmid SV, Jordan S, Lee GS, et al.  Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998;66:1604–1611
  36. Milpied N, Antoine C, Garnier JL, et al.  Humanized anti-CD20 monoclonal antibody (rituximab) in B posttransplant lymphoproliferative disorders (B PTLDs): A retrospective analysis of 32 patients. Ann Oncol. 1999;10(suppl 13, abstr):5
  37. Morra M, Howie D, Grande MS, et al.  X-linked lymphoproliferative disease: A progressive immunodeficiency. Ann Rev Immunol. 2001;19:657–682
  38. Mroczek EL, Weisenburger DD, Grierson HL, et al.  Fatal infectious mononucleosis and virus associated hemopagocytic syndrome. Arch. Pathol Lab Med. 1987;11:530–535
  39. Nakajima H, Cella M, Bouchon A, et al.  Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol. 2000;30:3309–3318
  40. Nichols KE, Harkin DP, Levitz S, et al.  Inactivatiing mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA. 1998;95:13765–13770
  41. Nichols KE. X-linked lymphoproliferative disease: Genetics and biochemistry. Rev Immunogenet. 2000;2:256–266
  42. Okano M, Gross TG. Epstein-Barr virus-associated hemophagocytic syndrome and fatal infectious mononucleosis. Am J Hematol. 1996;53:111–115
  43. O'Reilly RJ, Small TN, Papadopoulos E, et al.  Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195–216
  44. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al.  Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337:320–322
  45. Paya CV, Fung JJ, Nalesnik MA, et al.  Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation. 1999;68:1517–1525
  46. Pelletier LL, Borel DM, Romig DA, et al.  Disseminated intravascular coagulation and hepatic necrosis. Complications of infectious mononucleosis. JAMA. 1976;235:1144–1146
  47. Pipp ML, Means ND, Sixbey JW, et al.  Acute Epstein-Barr virus infection complicated by severe thrombocytopenia. Clin Infect Dis. 1997;15:1237–1239
  48. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant patients. Blood. 1994;84:972–984
  49. Rooney CM, Smith CA, Ng YC, et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphomas in allogeneic transplant recipients. Blood. 1998;92:1549–1555
  50. Sayos J, Wu C, Morra M, et al.  The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395:462–469
  51. Schooley RT, Densen P, Harmon D, et al.  Antineutrophil antibodies in infectious mononucleosis. Am J Med. 1984;76:85–90
  52. Seemayer TA, Gross TG, Egeler RM, et al.  X-linked lymphoproliferative disease: Twenty-five years after the discovery. Pediatr Res. 1995;38:471–478
  53. Setsuda J, Teruya-Feldsztein J, Harris NL, et al.  Interleukin-18, interferon-γ, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol. 1999;155:257–265
  54. Socinski MA, Ershler WB, Tosato G, et al.  Pure red cell aplasia associated with chronic Epstein-Barr virus infection: Evidence for T-cell mediated suppression of erythroid colony forming unit. J Lab Clin Med. 1984;104:995–1006
  55. Starzl TE, Nalesnik MA, Porter KA, et al.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583–587
  56. Sullivan JL. Hematologic consequences of Epstein-Barr virus infection. Hematol Oncol Clin North Am. 1987;1:397–417
  57. Sumaya CV, Ench Y. Epstein-Barr virus infectious mononucleosis in children. I. Clinical and general laboratory findings. Pediatrics. 1985;75:1003–1010
  58. Sumegi J, Huang D, Lanyi A, et al.  Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118–3125
  59. Swinnen LJ, Mullen GM, Carr TJ, et al.  Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86:3333–3340
  60. Sylla BS, Murphy K, Cahir-McFarland , et al.  The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-κB. Proc Natl Acad Sci USA. 2000;97:7470–7475
  61. Taga K, Chretien J, Cherney B, et al.  Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J Clin Invest. 1994;94:251–260
  62. Tan LC, Gudgeon N, Annels NE, et al.  A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162:1827–1835
  63. Tomkinson BE, Wagner DK, Nelson DL, et al.  Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol. 1987;139:3802–3807
  64. Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis. 1999;31:543–547
  65. Tosato G, Magrath I, Koski I, et al.  Activation of suppressor T cells during Epstein-Barr virus-induced infectious mononucleosis. N Engl J Med. 1979;301:1133–1137
  66. Tynell E, Aurelius E, Brandell A, et al.  Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double blind, placebo-controlled study. J Infect Dis. 1996;174:324–331
  67. Van Esser JWJ, Niesters HGM, van der Holt B, et al.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–4669
  68. Whitelaw F, Brook MG, Kennedy N, et al.  Haemolytic anaemia complicating Epstein-Barr virus infection. Br J Clin Pract. 1995;49:212–213
  69. Wu C, Nguyen KB, Pien GC, et al.  SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nat Immunol. 2001;2:410–414

☆ This is a US government work. There are no restrictions on its use.

☆☆ 0037-1963/03/4002-0002$0.00/0

PII: S0037-1963(03)70003-1

Seminars in Hematology
Volume 40, Issue 2 , Pages 116-123 , April 2003

Article Tools